A nationwide Swiss study found significant increases in cannabis-related psychiatric hospitalizations from 1998 to 2020, with the highest rates among 15-24 and 25-44 year olds.
Public health officials; cannabis policy researchers; psychiatrists seeing cannabis-related cases.
Sharp increase in cannabis psychiatric hospitalizations across 1998-2020
What the researchers found
Cannabis-related psychiatric hospitalization rates increased significantly from 1998 to 2020. These diagnoses were disproportionately represented in the 15-24 and 25-44 age groups compared to other psychiatric diagnoses. The trend was compared against alcohol-related and psychotic disorder hospitalizations.
Why it matters
Population-level hospitalization trends provide hard data on the public health impact of cannabis. The concentration in younger age groups aligns with neurobiological evidence about adolescent vulnerability and has direct implications for Swiss cannabis policy reform.
The numbers in context
Data covered all psychiatric inpatients in Switzerland from 1998-2020. Cannabis-related diagnoses were significantly overrepresented in ages 15-24 and 25-44. The study documented a "sharp increase" in cannabis-related hospitalizations over the observation period.
How the study worked
Nationwide analysis using Swiss Federal Statistics Office data covering all psychiatric inpatient cases in Switzerland from 1998 to 2020. Trend analyses compared cannabis-related diagnoses to alcohol-related and psychotic disorder hospitalization rates by age group, gender, and region.
What this study cannot tell us
Hospitalization data may not capture the full picture, as many cannabis-related psychiatric issues are managed outpatient. Changes in diagnostic coding practices or clinician awareness could contribute to trend increases. Causation cannot be established from trend data alone.
How to read the evidence
Strong: nationwide data covering all psychiatric inpatients across 22 years from a federal statistics office.
When this study was published
Published in 2022, covering data from 1998-2020.
The bigger picture
Switzerland is actively considering cannabis regulation reform. This nationwide hospitalization data provides important context for policy decisions, showing that cannabis-related psychiatric burden has been growing independent of formal legalization.
Questions still open
- Would regulated cannabis access with age restrictions and quality controls reduce psychiatric hospitalization rates? Are the increasing trends driven by higher potency products, increased use, or better clinical recognition?
Common questions
Are more people being hospitalized for cannabis problems?
Does this mean cannabis is more dangerous than before?
Read the original research
A Nationwide Study of Inpatient Case Rate Incidence of Cannabis-Related Diagnoses in Switzerland.
International journal of public health, 67, 1605554
Citation
Pfeifer, Philippe; Auer, Reto; Baggio, Stéphanie; Moggi, Franz. (2022). A Nationwide Study of Inpatient Case Rate Incidence of Cannabis-Related Diagnoses in Switzerland.. International journal of public health, 67, 1605554. https://doi.org/10.3389/ijph.2022.1605554
Explore the wider topic
- LGBTQ+ and Cannabis: Higher Use Rates and Recovery
- Cannabis-Induced Psychosis: What It Is, Who's at Risk, and What to Do
- BetterHelp, Cerebral, and Online Therapy: Honest Review
- Quitting Weed with ADHD: Why It Is Harder and What Actually Helps
- Quitting Weed with Depression: What You Need to Know
- Quitting Weed with PTSD: A Practical Guide
- Self-Medicating with Weed: Why It Works Until It Doesn't
- Weed and OCD: Self-Medicating Intrusive Thoughts
- Weed and PTSD: What the Research Actually Shows
- Weed and Childhood Trauma: ACEs, Self-Medication, and the Path to Real Healing
- Weed and Suicidal Thoughts: What You Need to Know